marketbeat.com · 11 jul

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression.

globenewswire.com · 10 jul

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

globenewswire.com · 9 jul

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.

seekingalpha.com · 7 jul

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

reuters.com · 7 jul

US FDA approves Vera's kidney disease drug

The ​U.S. Food and Drug Administration ‌has approved Vera Therapeutics' drug to treat patients with ​a potentially life-threatening kidney ​disease, the regulator said ⁠on Tuesday, sending its ​shares up 6.2% in afternoon ​trading.

globenewswire.com · 7 jul

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).1,2 The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.1 Investor webcast is scheduled for July 7 at 4:30 pm EDT. A Media Snippet accompanying this announcement is available by clicking on this link.

benzinga.com · 6 jul

What's Going on with Vera Therapeutics Stock on Monday?

Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. Food and Drug Administration (FDA) decision for its rare kidney disease drug.

marketbeat.com · 23 jun

3 Biotech Firms With Major Potential Catalysts in the Coming Months

As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.